The evolution of brain atrophy across the disease spectrum of familial frontotemporal dementia

Background Familial frontotemporal dementia (f‐FTLD) is typically caused by mutations in one of three genes: microtubule‐associated protein tau (MAPT), progranulin (GRN), and a repeat expansion in the chromosome 9 open reading frame 72 (C9orf72) gene. Accurate characterization of the natural history...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Alzheimer's & dementia 2020-12, Vol.16, p.n/a
Hauptverfasser: Staffaroni, Adam M., Goh, Sheng‐Yang Matthew, Cobigo, Yann, Ong, Elise, Lee, Suzee E., Casaletto, Kaitlin B., Wolf, Amy, Forsberg, Leah K., Ghoshal, Nupur, Graff‐Radford, Neill R., Grossman, Murray, Heuer, Hilary W., Hsiung, Ging‐Yuek Robin, Kantarci, Kejal, Knopman, David S., Kremers, Walter K., Mackenzie, Ian R., Miller, Bruce L., Pedraza, Otto, Rascovsky, Katya, Tartaglia, Carmela, Wszolek, Zbigniew, Kramer, Joel H., Kornak, John, Boeve, Bradley F., Boxer, Adam L., Rosen, Howard J.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Familial frontotemporal dementia (f‐FTLD) is typically caused by mutations in one of three genes: microtubule‐associated protein tau (MAPT), progranulin (GRN), and a repeat expansion in the chromosome 9 open reading frame 72 (C9orf72) gene. Accurate characterization of the natural history of each mutation is important for clinical prognostication and clinical trial design, and it could shed light on disease biology. Such models have not been thoroughly developed using participants that represent all disease stages, with longitudinal data. We characterized the trajectory of atrophy in each gene by using longitudinal voxel‐wise analyses of gray matter volume, and we assessed whether functional independence declined in tandem. Method F‐FTLD participants (n=100) with a known mutation (MAPT+ (n=28), GRN+ (n=33), C9orf72+ (n=39)) were grouped according to disease stage (CDR®+NACC FTLD module). We included participants with at least two structural MRIs at a given disease stage: presymptomatic (CDR®+NACC‐FTLD=0, n=57), mild/questionable (CDR®+NACC‐FTLD=0.5, n=15), and symptomatic (CDR®+NACC‐FTLD ≥1, n=28). We fitted longitudinal linear mixed effects models to extract mean atrophy rates in each lobe compared to longitudinal imaging from family members without mutations (n=60). All results presented below were significant at p
ISSN:1552-5260
1552-5279
DOI:10.1002/alz.046404